BASE - Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.
G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million.
G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday.
Here are some other stocks moving in today’s mid-day session.
Gainers
- Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390.
- American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded radiation oncology services with opening of Low Country Radiation in Waycross, Georgia.
- Latam Logistic Properties, S.A. (NYSE:LPA) shares gained 99.2% to $63.01 after dipping around 83% on Wednesday.
- Freight Technologies, Inc. (NASDAQ:FRGT) shares climbed 90.4% to $1.1950 after the company said it added 26 new customers and 149 new carriers in 2024.
- Aethlon Medical, Inc. (NASDAQ:AEMD) gained 67.7% to $0.7361 after jumping 7% on Wednesday.
- China Liberal Education Holdings Limited (NASDAQ:CLEU) rose 42% to $2.04.
- iSpecimen Inc. (NASDAQ:ISPC) rose 38.3% to $0.4442 after declining 4% on Wednesday.
- Nauticus Robotics, Inc. (NASDAQ:KITT) shares rose 31.5% to $0.1815 after gaining around 20% on Wednesday. Nauticus Robotics, last month, announced a deal with H.C. Wainwright & Co to sell shares under an at-the-market offering.
- Pixie Dust Technologies, Inc. (NASDAQ:PXDT) gained 29% to $2.13.
- Tungray Technologies Inc. (NASDAQ:TRSG) rose 28.8% to $4.25.
- iSpecimen Inc. (NASDAQ:ISPC) gained 27.6% to $0.4097.
- Replimune Group, Inc. (NASDAQ:REPL) gained 27.3% to $7.08 as the company announced positive topline primary analysis data by Independent Central Review from IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) gained 26.7% to $6.40 after Cycle Pharmaceuticals confirmed that it made a proposal to buy the company.
- Co-Diagnostics, Inc. (NASDAQ:CODX) gained 22.3% to ...